United Therapeutics (UTHR) Revenue by Segment

History

Date	Tyvaso	Remodulin	Orenitram	Unituxin	Adcirca	Other
Dec 31, 2025	1.88B	526.80M	496.90M	226.80M	30.00M	24.00M
Sep 30, 2025	1.83B	533.30M	483.50M	232.00M	26.90M	22.90M
Jun 30, 2025	1.79B	535.70M	465.60M	245.20M	24.20M	21.50M
Mar 31, 2025	1.71B	548.30M	448.80M	238.50M	23.40M	20.90M
Dec 31, 2024	1.62B	538.10M	434.30M	238.70M	23.80M	22.10M
Sep 30, 2024	1.56B	518.70M	410.60M	225.40M	25.90M	20.50M
Jun 30, 2024	1.45B	521.50M	389.40M	215.60M	26.20M	16.90M
Mar 31, 2024	1.37B	501.40M	377.40M	208.20M	28.00M	12.00M
Dec 31, 2023	1.23B	494.80M	359.40M	198.90M	28.90M	8.30M
Sep 30, 2023	1.13B	502.20M	351.10M	181.40M	32.50M	8.20M
Jun 30, 2023	1.06B	485.10M	346.60M	176.20M	35.90M	6.30M
Mar 31, 2023	939.40M	489.90M	330.50M	176.40M	38.80M	6.30M
Dec 31, 2022	873.00M	500.20M	325.10M	182.90M	41.30M	13.80M
Sep 30, 2022	797.20M	496.00M	321.60M	196.20M	39.00M	10.00M
Jun 30, 2022	703.70M	507.40M	319.30M	205.40M	42.90M	10.00M
Mar 31, 2022	656.50M	515.20M	316.50M	214.00M	56.10M	10.00M
Dec 31, 2021	607.50M	513.70M	306.10M	202.30M	55.90M	-
Sep 30, 2021	572.70M	523.30M	307.80M	182.00M	69.40M	-
Jun 30, 2021	538.00M	522.40M	297.30M	164.30M	68.60M	-
Mar 31, 2021	503.40M	501.60M	296.50M	140.20M	64.40M	-

Source: Business metrics provided by TipRanks and sourced from official company press releases and documents.